Monthly Headaches and Severity in Patients on Galcanezumab or Traditional Preventive Migraine Medication: A 24-Month Claims and Electronic Health Records Study
In this exploration of multiple data sources and methodologies, changes in MHDs over 24 months were small in patients treated with galcanezumab or SOC. While real-world data from administrative claims and EHR provided insights, limitations such as small sample sizes for migraine severity data and challenges in extracting clinical outcomes underscore the need for further research.
Authors
- Gilwan Kim (ORCID: https://orcid.org/0000-0003-1991-6644)
- Margaret Hoyt (ORCID: https://orcid.org/0000-0002-9486-2095)
- Ashish Nayyar (ORCID: https://orcid.org/0000-0001-8037-3621)
- Michelle Vu (ORCID: https://orcid.org/0000-0003-0795-1688)
- Oralee J. Varnado (ORCID: https://orcid.org/0000-0001-8054-2544)
- Erin Buysman (ORCID: https://orcid.org/0000-0003-0104-5836)
- Lars Viktrup (ORCID: https://orcid.org/0000-0002-8739-0544)
- Shikha Anand
Institutions
- Eli Lilly (United States) (US)
- Optum (United States) (US)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1007/s40120-025-00742-w
- Citations
- 1
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Eli Lilly and Company